News
Mature overall survival results of the INAVO120 trial were presented in a press conference for the American Society of ...
1d
Medpage Today on MSNSurvival Win With Inavolisib-Based Triplet in PIK3CA-Mutated Breast CancerCHICAGO -- Adding the PI3K-pathway inhibitor inavolisib (Itovebi) to palbociclib (Ibrance) and fulvestrant significantly ...
1d
Medpage Today on MSNStudy Links GLP-1 Drugs to Lower Cancer RiskThe findings add to other research showing a lower risk of obesity-related cancers in patients taking GLP-1 drugs, a class of ...
AstraZeneca is putting the pedal to the metal to drive up early detection of prostate cancer. | AstraZeneca is putting the ...
A Google Translate screenshot correctly shows that the name of the pharmaceutical company AstraZeneca, when written as “A ...
Successful trial results in the next few years could save thousands of lives and generate billions in new annual revenue for ...
ZoomRx polled 50 experienced oncologists and hemato-oncologists about 20 cancer drugmakers, asking the doctors to rank the ...
2d
Zacks Investment Research on MSNAstraZeneca Stock Declines 6% in 3 Months: Time to Buy the Dip?AstraZeneca AZN stock has declined 6.4% in the past three months. Although AstraZeneca faces its share of challenges, a ...
Kicking off this week in Chicago, this year’s American Association for Cancer Research conference will feature presentations ...
15h
Pharmaceutical Technology on MSNAptar Digital to use AstraZeneca’s AI algorithms for CKD detectionThe collaboration aims to integrate these algorithms into routine eye examinations, facilitating the diagnosis of CKD.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results